SciClone licenses Tarveda's preclinical HSP90-PI3K miniature drug conjugates for Greater...
Elise Mak · 09/17/2021
SciClone has licensed in the Greater China rights to a preclinical-stage product portfolio of miniature drug conjugates that consist of a PI3K inhibitor payload moiety, a linker, and an HSP90 binding moiety.
READ MORE
IASO bags $108M Series C to advance cell therapy
Elise Mak · 09/17/2021
The CAR-T therapy developer has raised more than $178 million since its establishment in 2017.
READ MORE
Led by Abogen, infectious disease drugmakers post re...
Minhua Chu · 09/17/2021
Chinese biotech companies raised a total of $2.64 billion from 28 disclosed deals in August.
READ MORE
After mRNA, Everest gains BTK inhibitor in $561M dea...
Elise Mak · 09/17/2021
Everest will pay Suzhou Sinovent and SinoMab BioScience up to $561 million to license the global rights to BTK inhibitor XNW1011, four days after the mRNA transaction with Providence that is worth over $500 million.
READ MORE
BeiGene's Brukinsa wins FDA approval in marginal zon...
Elise Mak · 09/16/2021
BeiGene's BTK inhibitor Brukinsa received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory (r/r) marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.
READ MORE
InnoCare seeks $621M STAR listing
Elise Mak · 09/16/2021
Cancer drug developer InnoCare, known for its BTK inhibitor Yinuokai (orelabrutinib), is now seeking to raise RMB4 billion ($621 million) on Shanghai's STAR market.
READ MORE
Alebund bags $54.5M Series B+ to target renal diseas...
Elise Mak · 09/15/2021
Alebund Pharmaceuticals, a renal disease specialist based in Shanghai, has secured $54.5 million in a Series B+ round to support its clinical programs and construction of a manufacturing site. The pro
READ MORE
MingMed raises $50M Series A+ to support U.S. eye dr...
Elise Mak · 09/15/2021
MingMed, which was founded in October 2019, boasts a pipeline that covers ophthalmology, small molecule immuno-oncology, gene editing-based immunotherapy, medical aesthetics, and pet medicine.
READ MORE
Cytovia and its China JV secures $45M to develop NK ...
Elise Mak · 09/15/2021
Cytovia Therapeutics and its Chinese joint venture CytoLynx Therapeutics have raised $45 million to move their cell therapy candidates to IND stage and support the trials.
READ MORE
READ MORE
Copyright © 2016-2021 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement